China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced a licensing agreement with Denmark-headquartered MC2 Therapeutics A/S, securing exclusive development and commercialization rights to MC2’s Wynzora cream, a therapy for plaque psoriasis. The agreement covers the Greater China territory, which includes mainland China, Hong Kong, Macau, and Taiwan.
Financial Terms and Milestones of the Agreement
According to the terms of the agreement, MC2 Therapeutics will receive upfront and regulatory milestone payments totaling USD 16 million, with an additional USD 36 million contingent upon achieving certain sales milestones. MC2 is also eligible to receive tiered double-digit royalties on sales. Huadong Medicine will take on the responsibility for the development and commercialization of Wynzora cream in Greater China, under the oversight of a joint steering committee composed of representatives from both companies.
Wynzora Cream: A Dual-Action Plaque Psoriasis Treatment
Wynzora cream is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate, designed for the topical treatment of plaque psoriasis, including scalp psoriasis, in adults. Its dual mode of action targets the IL-23 and IL-17A/F immune axis, as well as TNF-α expression, in a single product. The product has been approved in the US and Europe in July 2020 and July 2021, respectively, marking its potential efficacy and safety profile.-Fineline Info & Tech
